药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Mecasermin
Dabrafenib
The metabolism of Brentuximab vedotin can be increased when combined with Dabrafenib.
Mecasermin
Avasimibe
The metabolism of Brentuximab vedotin can be increased when combined with Avasimibe.
Mecasermin
Midostaurin
The metabolism of Brentuximab vedotin can be increased when combined with Midostaurin.
Mecasermin
Aripiprazole lauroxil
The metabolism of Aripiprazole lauroxil can be decreased when combined with Brentuximab vedotin.
Mecasermin
Odesivimab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Odesivimab.
Mecasermin
Maftivimab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Maftivimab.
Mecasermin
Atoltivimab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Atoltivimab.
Mecasermin
Zenocutuzumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Zenocutuzumab.
Mecasermin
Polatuzumab vedotin
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Polatuzumab vedotin.
Mecasermin
Ustekinumab
The risk or severity of adverse effects can be increased when Ustekinumab is combined with Brentuximab vedotin.
Mecasermin
Tildrakizumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tildrakizumab.
Mecasermin
Naratuximab emtansine
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Naratuximab emtansine.
Mecasermin
Lorukafusp alfa
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Lorukafusp alfa.
Mecasermin
Lulizumab pegol
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Lulizumab pegol.
Mecasermin
Pinatuzumab vedotin
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Pinatuzumab vedotin.
Mecasermin
Vesencumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Vesencumab.
Mecasermin
Tomaralimab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tomaralimab.
Mecasermin
Ladiratuzumab vedotin
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Ladiratuzumab vedotin.
Mecasermin
GMA-161
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with GMA-161.
Mecasermin
Pidilizumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Pidilizumab.